Roche pushes late-comer Tecentriq as new liver cancer option
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Health | Immunotherapy | Liver | Switzerland Health | Urology & Nephrology